S&P 500 7,628.29 â–ŧ 57.85 (-0.75%) DOW 52,759.94 â–ŧ 425.96 (-0.80%) NASDAQ 26,096.35 â–ŧ 274.54 (-1.04%) US Markets Closed â€ĸ 04:07 PM ET

PBMWW

Psyence Biomedical Ltd.

Price Chart

No historical data available

Latest Quote

$0.02

+0.00 (+0.00%)
Current Price
Previous Close $0.02
Open $0.02
Day High $0.02
Day Low $0.02
Volume 4,414
Fetched: 2026-09-01T14:03:26
Stock Information
Cash Equivalents $7.44M
Net Income $-6.94M
Exchange NCM
🌐 Visit Website
Recent Price History
No history data available. Data will be fetched automatically.
About Psyence Biomedical Ltd.

Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.

📰 Latest News
No news articles available at the moment. Check back later for updates on PBMWW.
Period:
Loading...
Income Statement (Annual)
Metric 2026-03-31 2025-03-31 2024-03-31 2023-03-31
Revenue
Total Revenue $0 $0 $0 $0
Operating Revenue $0 $0 $0 $0
Expenses
Interest Expense $9,522 $9,270 $52,941 $0
Total Expenses $5,945,264 $3,663,022 $43,354,085 $3,234,869
Other Income Expense $-1,245,005 $4,588,295 $-7,754,155 $26,912
Other Non Operating Income Expenses $-110,242 $4,063,193 $-5,265,685 -
Net Non Operating Interest Income Expense $253,848 $86,517 $-50,807 $1,554
Interest Expense Non Operating $9,522 $9,270 $52,941 $0
Operating Expense $5,945,264 $3,663,022 $43,354,085 $3,234,869
Other Operating Expenses $-292,247 - $40,602,261 -
Selling And Marketing Expense $218,485 $483,530 $80,603 $7,029
General And Administrative Expense $4,547,107 $2,833,056 $1,716,388 $1,618,945
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $-6,936,421 $1,011,790 $-51,159,048 $-3,206,403
Net Interest Income $253,848 $86,517 $-50,807 $1,554
Interest Income $263,370 $95,787 $2,134 $1,554
Normalized Income $-5,846,897 $565,453 $-48,670,578 $-3,233,315
Net Income From Continuing And Discontinued Operation $-6,936,421 $1,011,790 $-51,159,048 $-3,206,403
Net Income Common Stockholders $-6,936,421 $1,011,790 $-51,159,048 $-3,206,403
Net Income $-6,936,421 $1,011,790 $-51,159,048 $-3,206,403
Net Income Including Noncontrolling Interests $-6,936,421 $1,011,790 $-51,159,047 $-3,206,403
Net Income Continuous Operations $-6,936,421 $1,011,790 $-51,159,047 $-3,206,403
Pretax Income $-6,936,421 $1,011,790 $-51,159,047 $-3,206,403
Special Income Charges $-1,500,000 $0 $-2,179,525 $0
Earnings From Equity Interest $-45,239 $0 $0 -
Interest Income Non Operating $263,370 $95,787 $2,134 $1,554
Operating Income $-5,945,264 $-3,663,022 $-43,354,085 $-3,234,869
Depreciation Amortization Depletion Income Statement $5,266 $4,268 $240 $0
Depreciation And Amortization In Income Statement $5,266 $4,268 $240 $0
Depreciation Income Statement $5,266 $4,268 $240 $0
Other
Tax Effect Of Unusual Items $0 $78,765 $0 $0
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $-5,832,109 $500,226 $-48,617,396 $-3,233,315
Total Unusual Items $-1,089,524 $525,102 $-2,488,470 $26,912
Total Unusual Items Excluding Goodwill $-1,089,524 $525,102 $-2,488,470 $26,912
Reconciled Depreciation $5,266 $4,268 $240 $0
EBITDA (Bullshit earnings) $-6,921,633 $1,025,328 $-51,105,866 $-3,206,403
EBIT $-6,926,899 $1,021,060 $-51,106,106 $-3,206,403
Diluted NI Availto Com Stockholders $-6,936,421 $1,011,790 $-51,159,048 $-3,206,403
Other Special Charges $1,500,000 - $-281,500 -
Restructuring And Mergern Acquisition $0 $0 $2,461,025 $0
Gain On Sale Of Security $410,476 $525,102 $-308,945 $26,912
Research And Development $1,466,653 $342,168 $954,593 $1,608,895
Selling General And Administration $4,765,592 $3,316,586 $1,796,991 $1,625,974
Other Gand A $4,547,107 $2,833,056 $1,716,388 $1,618,945
Fetched: 2026-08-28
Balance Sheet (Annual)
Metric 2026-03-31 2025-03-31 2024-03-31 2023-03-31
Assets
Net Tangible Assets $16,944,130 $6,722,004 $-10,972,540 $-200,445
Total Assets $17,567,320 $7,316,370 $1,132,159 $1,590,255
Total Non Current Assets $8,456,745 $756,096 $5,487 $0
Investmentin Financial Assets $0 $745,000 $0 -
Financial Assets Designatedas Fair Value Through Profitor Loss Total $0 $745,000 $0 -
Current Assets $9,110,575 $6,560,274 $1,126,672 $1,590,255
Restricted Cash $47,191 $35,964 $29,611 $29,556
Prepaid Assets $1,255,857 $251,796 $322,126 $77,050
Receivables $362,764 $137,348 $41,747 $149,369
Other Receivables $109,779 $137,348 $41,747 $149,369
Loans Receivable $252,985 $0 - -
Cash Cash Equivalents And Short Term Investments $7,444,763 $6,135,166 $733,188 $1,334,280
Cash And Cash Equivalents $7,444,763 $6,135,166 $733,188 $1,334,280
Cash Financial $7,444,763 $6,135,166 $733,188 $1,334,280
Debt
Net Debt - - $9,714,701 -
Total Debt - - $10,447,889 -
Current Debt And Capital Lease Obligation - - $10,447,889 -
Current Debt - - $10,447,889 -
Other Current Borrowings - - $10,447,889 -
Liabilities
Total Liabilities Net Minority Interest $623,190 $594,366 $12,104,699 $1,790,700
Total Non Current Liabilities Net Minority Interest $0 $0 $0 $0
Current Liabilities $623,190 $594,366 $12,104,699 $1,790,700
Other Current Liabilities $215,476 $200,096 $901,608 -
Payables And Accrued Expenses $314,193 $312,418 $688,303 $1,790,700
Payables $229,509 $261,937 $562,352 $1,628,143
Accounts Payable $229,509 $261,937 $562,352 $1,628,143
Equity
Common Stock Equity $16,944,130 $6,722,004 $-10,972,540 $-200,445
Total Equity Gross Minority Interest $16,944,130 $6,722,004 $-10,972,540 $-200,445
Stockholders Equity $16,944,130 $6,722,004 $-10,972,540 $-200,445
Other Equity Interest $1,183,595 $1,065,705 - $-200,558
Gains Losses Not Affecting Retained Earnings $396,177 $351,198 $361,057 $165,360
Retained Earnings $-63,383,625 $-56,447,204 $-57,458,994 $-6,299,946
Long Term Equity Investment $8,060,928 $0 - -
Other
Ordinary Shares Number $2,293,277 $90,883 $3,584 $3,411
Share Issued $2,293,277 $90,883 $3,584 $3,411
Tangible Book Value $16,944,130 $6,722,004 $-10,972,540 $-200,445
Invested Capital $16,944,130 $6,722,004 $-524,651 $-200,445
Working Capital $8,487,385 $5,965,908 $-10,978,027 $-200,445
Total Capitalization $16,944,130 $6,722,004 $-10,972,540 $-200,445
Capital Stock $78,747,983 $61,752,305 $46,125,397 $5,934,141
Common Stock $78,747,983 $61,752,305 $46,125,397 $5,934,141
Current Provisions $93,521 $81,852 $66,899 -
Current Accrued Expenses $84,684 $50,481 $125,951 $162,557
Investments And Advances $8,450,686 $745,000 $0 -
Other Investments $389,758 $0 - -
Investmentsin Associatesat Cost $8,060,928 $0 - -
Net PPE $6,059 $11,096 $5,487 $0
Accumulated Depreciation $-9,774 $-4,508 $-240 $0
Gross PPE $15,833 $15,604 $5,727 $0
Machinery Furniture Equipment $15,833 $15,604 $5,727 -
Other Properties - - $5,727 -
Fetched: 2026-08-28
Cash Flow Statement (Annual)
Metric 2026-03-31 2025-03-31 2024-03-31 2023-03-31
Free Cash Flow
Free Cash Flow $-8,643,236 $-3,744,115 $-2,951,092 $-1,592,080
Operating Activities
Operating Cash Flow $-8,143,007 $-3,734,238 $-2,945,365 $-1,592,080
Cash Flow From Continuing Operating Activities $-8,143,007 $-3,734,238 $-2,945,365 $-1,592,080
Operating Gains Losses $215,840 $-519,312 $28,410 $-84,499
Investing Activities
Capital Expenditure $-500,229 $-9,877 $-5,727 -
Investing Cash Flow $-4,511,456 $-16,230 $-5,727 $0
Cash Flow From Continuing Investing Activities $-4,511,456 $-16,230 $-5,727 $0
Net Other Investing Changes $-11,227 $-6,353 - -
Financing Activities
Issuance Of Capital Stock $0 $1,742,051 $0 $0
Financing Cash Flow $13,964,060 $9,152,446 $2,350,000 $1,172,923
Cash Flow From Continuing Financing Activities $13,964,060 $9,152,446 $2,350,000 $1,172,923
Net Common Stock Issuance $0 $1,742,051 $0 $0
Common Stock Issuance $0 $1,742,051 $0 $0
Net Other Financing Charges - - - $1,172,923
Other
Repayment Of Debt $0 $0 $-150,000 $0
Issuance Of Debt $13,964,060 $7,410,395 $2,500,000 $0
End Cash Position $7,444,763 $6,135,166 $733,188 $1,334,280
Beginning Cash Position $6,135,166 $733,188 $1,334,280 $1,753,437
Changes In Cash $1,309,597 $5,401,978 $-601,092 $-419,157
Net Issuance Payments Of Debt $13,964,060 $7,410,395 $2,350,000 $0
Net Short Term Debt Issuance $0 $1,000,000 $2,350,000 $0
Short Term Debt Payments $0 $0 $-150,000 $0
Short Term Debt Issuance $0 $1,000,000 $2,500,000 $0
Net Long Term Debt Issuance $13,964,060 $6,410,395 $0 $0
Long Term Debt Issuance $13,964,060 $6,410,395 $0 $0
Net Business Purchase And Sale $-4,000,000 $0 $0 -
Purchase Of Business $-4,000,000 $0 $0 -
Net PPE Purchase And Sale $-500,229 $-9,877 $-5,727 $0
Purchase Of PPE $-500,229 $-9,877 $-5,727 $0
Change In Working Capital $-1,216,033 $-386,203 $-1,172,951 $1,477,535
Change In Payables And Accrued Expense $13,444 $-360,932 $-1,035,498 $1,659,058
Change In Prepaid Assets $-1,004,061 $70,330 $-245,075 $-71,665
Change In Receivables $-225,416 $-95,601 $107,622 $-109,858
Other Non Cash Items $-367,000 $218,412 $43,582,435 -
Stock Based Compensation $155,341 $0 $317,882 $221,287
Unrealized Gain Loss On Investment Securities $0 $-4,063,193 $5,457,667 $0
Depreciation Amortization Depletion $5,266 $4,268 $240 $0
Depreciation And Amortization $5,266 $4,268 $240 $0
Depreciation $5,266 $4,268 $240 $0
Earnings Losses From Equity Investments $45,239 $0 $0 -
Gain Loss On Investment Securities $15,380 $-509,452 $306,250 -
Net Foreign Currency Exchange Gain Loss $44,979 $-9,860 $3,660 $-84,499
Gain Loss On Sale Of PPE $110,242 $0 $0 -
Net Income From Continuing Operations $-6,936,421 $1,011,790 $-51,159,048 $-3,206,403
Gain Loss On Sale Of Business - $-22,967 $0 $0
Fetched: 2026-08-28